TAK-660-403

An app for the TAK-660-403 Protocol. Evaluation of long-term safety of ADYNOVI / ADYNOVATE(Antihaemophilic Factor [Recombinant] PEGylated, rurioctocog alfa pegol) in patients with haemophilia A – An ADYNOVI / ADYNOVATE Post-Authorisation Safety Study (PASS)